NCT04501276 2026-01-08A Phase 1b/2 Study of ADG116, ADG116 Combined With Anti-PD-1 Antibody or Anti-CD137 Antibody in Solid Tumors PatientsAdagene IncPhase 1 Completed72 enrolled
NCT05277402 2024-02-26ADG116 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid TumorsAdagene IncPhase 1 Completed6 enrolled